ID 83. SHORT-TERM EFFECTS OF SYSTEMIC HYDROCORTISONE INITIATED 7 TO 14 DAYS AFTER BIRTH IN VENTILATED VERY PRETERM INFANTS

Miss Nienke Halbmeijer¹, Dr. Wes Onland¹, Dr. Filip Cools², Dr. Andre Kroon³, Dr. Marja van der Heide-Jalving³, Dr. Peter Dijk³, Dr. Henrica van Straaten⁴, Dr. Arjan te Pas⁴, Dr. Thilo Mohns⁵, Dr. Els Bruneel⁶, Dr. Arno van Heijst⁶, Dr. Boris Kramer¹⁰, Dr. Anne Debeer¹¹, Dr. Inge Zonnenberg¹², Dr. Yoann Marechal¹³, Dr. Henry Blom¹⁴, Dr. Katleen Plaskie¹⁵, Dr. Martin Offringa¹⁶, Prof. Dr. Anton van Kaam¹
¹Department of Neonatology, Emma Children’s Hospital, Amsterdam Reproduction & Development research institute, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands, ²Department of Neonatology, Universitair Ziekenhuis Brussel, Brussel, Belgium, ³Department of Neonatology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands, ⁴Department of Neonatology, Isala Medical Center, Zwolle, The Netherlands, ⁵Department of Neonatology, University Medical Center Groningen, Beatrix Children’s Hospital, University of Groningen, Groningen, The Netherlands, ⁶Department of Neonatology, Leiden University Medical Center, Leiden, The Netherlands, ⁷Department of Neonatology, Maxima Medical Center, Veldhoven, The Netherlands, ⁸Department of Neonatology, Ziekenhuis Oost-Limburg, Genk, Belgium, ⁹Department of Neonatology, Radboud University Medical Center-Amalia Childrens Hospital, Nijmegen, The Netherlands, ¹⁰Department of Neonatology, Maastricht University Medical Center, Maastricht, The Netherlands, ¹¹Department of Neonatology, Universitair ziekenhuis Leuven, Leuven, Belgium, ¹²Department of Neonatology, University Medical Center Utrecht, Utrecht, The Netherlands, ¹³Department of Neonatology, Centre Hospitalier Universitaire de Charleroi, Charleroi, Belgium, ¹⁴Department of Neonatology, Universitair Ziekenhuis Antwerpen, Antwerpen, Belgium, ¹⁵Department of Neonatology, St Augustinus ziekenhuis, Antwerpen, Belgium, ¹⁶Division of Neonatology and Child Health Evaluative Sciences, the Hospital for Sick Children Research Institute, University of Toronto, Toronto, Canada

BACKGROUND
The Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD) study is the first large randomized placebo-controlled trial investigating the effect of systemic hydrocortisone treatment initiated in the second week of life in ventilator-dependent preterm infants on the primary outcome death or bronchopulmonary dysplasia at 36 weeks’ postmenstrual age. In the current study, we performed a secondary in-depth analysis of the short-term pulmonary and systemic effects of hydrocortisone treatment based on the data collected in the SToP-BPD study.

METHODS
Eligible preterm infants with a gestational age <30 weeks and/or birth weight <1250 grams were randomly assigned between 7-14 days of life to a 22-day course of systemic hydrocortisone (cumulative dose 72.5 mg/kg; n=182) or placebo (n=190). Data on extubation, ventilator mode and settings, blood glucose levels, and blood pressure were recorded daily during the 22-day treatment course. Changes over time during the first 7 days of treatment for the ventilator mode and settings, blood glucose levels, and blood pressure were compared between treatment groups with linear mixed effects models.

RESULTS
At the end of the 22-day treatment course, a significantly lower proportion of infants in the hydrocortisone group failed extubation compared to the placebo group (23.2% [42/181] vs 34.9% [66/189], respectively; crude risk difference, -11.7% [95% CI, -20.7% to -2.4%]). Mean airway pressure, fraction of inspired oxygen
and respiratory index decreased significantly over the first 7 days of treatment in infants treated with hydrocortisone compared to placebo (-0.42 cmH2O [95% CI, -0.48 to -0.35], -0.02 [95% CI, -0.02 to -0.01], and -0.37 [95%, CI -0.44 to -0.30], respectively; all p<0.001). Blood glucose levels and mean blood pressure increased significantly over the first 7 days in hydrocortisone treated infants (0.14 mmol/L [95% CI, 0.08 to 0.21] and 0.84 mmHg [95% CI, 0.58 to 1.09], respectively; both p<0.001).

CONCLUSION
Systemic hydrocortisone initiated between 7-14 days after birth in mechanically ventilated preterm infants born before 30 weeks’ gestation significantly improves the pulmonary condition, thereby facilitating weaning and extubation from invasive mechanical ventilation.

Figure 1. Changes over first 7 days of treatment in mean values for Respiratory Index (defined as MAWP x FiO2), with 95% confidence intervals analyzed with linear mixed effects models.

None declared